ALB and cancer: For targeted synthesisin cancer cells, GArM-Ru, an N-glycosylated albumin-basedArM, was employed, leveraging its affinity for galectin-8 in HeLacells (Figure A). The therapeutic efficacy of (33) + GArM-Ru wasvalidated in a murine tumor model.